1. Home
  2. BBIO vs FE Comparison

BBIO vs FE Comparison

Compare BBIO & FE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBIO
  • FE
  • Stock Information
  • Founded
  • BBIO 2015
  • FE 1996
  • Country
  • BBIO United States
  • FE United States
  • Employees
  • BBIO N/A
  • FE N/A
  • Industry
  • BBIO Biotechnology: Pharmaceutical Preparations
  • FE Electric Utilities: Central
  • Sector
  • BBIO Health Care
  • FE Utilities
  • Exchange
  • BBIO Nasdaq
  • FE Nasdaq
  • Market Cap
  • BBIO 9.4B
  • FE 23.9B
  • IPO Year
  • BBIO 2019
  • FE N/A
  • Fundamental
  • Price
  • BBIO $52.47
  • FE $43.55
  • Analyst Decision
  • BBIO Strong Buy
  • FE Buy
  • Analyst Count
  • BBIO 16
  • FE 16
  • Target Price
  • BBIO $64.44
  • FE $46.14
  • AVG Volume (30 Days)
  • BBIO 2.1M
  • FE 3.2M
  • Earning Date
  • BBIO 11-11-2025
  • FE 10-28-2025
  • Dividend Yield
  • BBIO N/A
  • FE 4.10%
  • EPS Growth
  • BBIO N/A
  • FE 49.18
  • EPS
  • BBIO N/A
  • FE 2.27
  • Revenue
  • BBIO $235,812,000.00
  • FE $13,864,000,000.00
  • Revenue This Year
  • BBIO $115.97
  • FE $8.73
  • Revenue Next Year
  • BBIO $65.50
  • FE $3.41
  • P/E Ratio
  • BBIO N/A
  • FE $19.12
  • Revenue Growth
  • BBIO 7.62
  • FE 6.52
  • 52 Week Low
  • BBIO $21.72
  • FE $37.58
  • 52 Week High
  • BBIO $54.60
  • FE $44.58
  • Technical
  • Relative Strength Index (RSI)
  • BBIO 57.70
  • FE 54.08
  • Support Level
  • BBIO $49.94
  • FE $43.05
  • Resistance Level
  • BBIO $52.72
  • FE $43.93
  • Average True Range (ATR)
  • BBIO 2.01
  • FE 0.49
  • MACD
  • BBIO -0.23
  • FE -0.07
  • Stochastic Oscillator
  • BBIO 58.45
  • FE 61.32

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About FE FirstEnergy Corp.

FirstEnergy is an investor-owned holding company with 10 regulated distribution utilities across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.

Share on Social Networks: